November 21, 2017 / 11:42 AM / a year ago

BRIEF-Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia​​

Nov 21 (Reuters) - Ardelyx Inc

* Ardelyx announces updated development path for its cardiorenal pipeline

* Ardelyx - second registration study for tenapanor for treatment of hyperphosphatemia will begin enrolling shortly​

* Ardelyx - second registration study for tenapanor will begin enrolling shortly after having received feedback from U.S. FDA on trial design

* Ardelyx Inc - ‍in addition, co reported clinically meaningful potassium lowering activity from its study for RDX7675 for treatment of hyperkalemia​

* Says ‍however, company also observed an unexpected side effect of decreased serum bicarbonate​

* Ardelyx Inc - ‍believes the side effect will limit commercial potential of RDX7675 and, as a result, has decided to discontinue development of RDX7675​

* Ardelyx inc - ‍ Ardelyx will shift its hyperkalemia efforts to RDX013, its earlier-stage, small-molecule program​

* Ardelyx Inc - the change will result in a cash savings of about $40 million to Ardelyx over next two years, extending co's operating runway into 2019​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below